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Abstract
Background: Pulmonary rehabilitation is known to be a beneficial treatment for COPD patients.
To date, however, there is no agreement for how long a rehabilitation program should be
implemented. In addition, current views are that pulmonary rehabilitation does not improve FEV1
or even slow its decline in COPD patients. The aim of the study was to examine the efficacy of a
3 year outpatient pulmonary rehabilitation (PR) program for COPD patients on pulmonary
function, exercise capability, and body mass index (BMI).
Methods: A matched controlled trial was performed with outcome assessments evaluated at 6,
12, 18, 24, 30, and 36 months. Eighty patients with moderate to severe COPD (age 63 ± 7 years;
FEV1 48% ± 14) were recruited. The control group received standard care only, while in addition,
the case study group received PR for duration of three years. These groups were matched for age,
sex, BMI, FEV1% and number of pack-years smoked.
Results: The decline in FEV1 after the three years was significantly lower in the PR group compared
to control, 74 ml versus 149 ml, respectively (p < 0.001). Maximal sustained work and endurance
time improved after a short period of PR and was maintained throughout the study, in contrast to
the control group (p < 0.01). A decreased BMI was noted in the control group after three years,
while in the PR group a mild improvement was seen (p < 0.05).
Conclusion: Three years of outpatient pulmonary rehabilitation resulted in modifying the disease
progression of COPD, as well as improving physical performance in these patients.
Background
Chronic obstructive pulmonary disease (COPD) is a
chronic progressive respiratory disorder causing disability
with an increasing burden to the patient, his family and to
the health services. Ppatients with COPD commonly
experience reduced exercise capacity and activity limita-
tion. Furthermore, exercise intolerance is a major determi-
nant of impaired quality of life for COPD patients, and
improvement in exercise capacity is a key goal of COPD
disease management [1].
Drug treatment regimens provides only partial benefit,
and many patients remain symptomatic with impaired
exercise capacity and and a worsening quality of life. For
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example, prospective studies testing for the effects of
inhaled short-acting anticholinergic drugs, inhaled corti-
costeroids, or N-acetylcysteine on the progression of
chronic obstructive pulmonary disease (COPD) failed to
demonstrate a change in the slope of the forced expiratory
volume in 1 second (FEV1) in these patients [2-4]. To date,
only smoking cessation has prospectively been shown to
alter the rate of decline of FEV1 in patients with COPD [5].
Pulmonary rehabilitation (PR) is used as a complemen-
tary treatment option for these patients, Recently, the
American Thoracic Society (ATS) and the European Tho-
racic Society (ERS) published a statement, in which PR
was recognized as an evidence-based, multidisciplinary,
and comprehensive intervention for patients with chronic
respiratory diseases who are symptomatic and often have
decreased daily life activities. [6]. This statement was fol-
lowed by a position paper by the ACCP/AACVPR that sup-
port and enhance the previously described statement [7].
One of the major unresolved issues is the duration of
treatment. For example, outpatient exercise training with
two or three weekly sessions for 4 weeks showed less ben-
efit than similar training for 7 weeks [8-10].
In order to evaluate the efficacy of pulmonary rehabilita-
tion to alter the course of disease in COPD, we carried out
in an outpatient setting, a controlled trial comparing 36
months of PR along with standard care and to the effects
of standard care without rehabilitation. The outcome
measurements included changes in the rate of FEV1
decline, its effects on exercise endurance and the change
of body mass index (BMI).
Methods
COPD patients who were on long acting beta agonist
(LABA) or combined inhalers of corticosteroids and
LABA, were matched for age, sex, BMI, FEV1% and
number of pack-years smoked into two groups, those
receiving pulmonary rehabilitation in addition to stand-
ard care and a control group receiving inhaled drugs as
described above [11]. Patients were eligible for inclusion
if they were younger than 70 years of age, had a FEV1 that
was less than 60% and higher than 30%, of predicted
value and their improvement after bronchodilator inhala-
tion (400 μg salbutamol) was less than 12%. In addition,
their clinical condition had been stable for at least 2
months prior to enrollment. We excluded patients who
were active smokers or had quit smoking less than 2 years
prior to the onset of this study and those in whom there
were other severe medical problems such as heart failure,
myocardial infarction, cerebrovascular disease, cancer, or
severe orthopedic disorders.
PR was carried out in groups of 6–8 patients, twice a week
during the course of the study. Each session consisted of
exercises of both upper and lower extremities as well as
integrated physical activity. This program was directed by
an exercise therapist. Patients were instructed to carry out
exercises at home simulating what they did in the groups,
on at least two additional days per week. In addition,
meetings on an individual basis with a psychologist,
sometimes with family members included, occurred as
needed. The patients were seen initially by the supervising
physician and at intervals of three months for routine fol-
low up and for functional evaluations. In addition, physi-
cian encounters occurred as needed. The control group
was similarly seen and assessed by a pulmonary physician
at three months intervals, in addition to as needed.
Pulmonary function studies were carried out at enroll-
ment and at intervals throughout the study period.
Spirometry (Medical Graphics, Inc., St. Paul, Minnesota)
including FEV1 and forced vital capacity, were measured
according to American Thoracic Society guidelines [12].
The BMI was re-calculated at every spirometry.
Exercise Endurance
During the run-in period, exercise tolerance was evaluated
with a constant-load cycle ergometer on two separate vis-
its. The constant-load tests were performed at 75% of the
maximal work rate achieved during the incremental exer-
cise test at screening. The purpose of the run-in exercise
tests was to familiarize the study subjects with the con-
stant-load exercise test procedures and reduce possible
learning effects [13]. Cycle endurance time was defined as
the duration of loaded pedaling. For the incremental test,
the initial work rate was 10 Watts (W) and the work rate
was increased by 10 W every minute until symptom limi-
tation. Pulse oximetry, ECG, and BP were monitored at
rest, during exercise, and at recovery.
Statistical Analysis
Data are presented as mean ± SD. Analysis of variance
(ANOVA) was used to compare between the groups for
analysis of the entire 36 months period. For time point
differences we used, a two-sample t test with a significance
level of 0.05.
Study ethics
The study was approved by the Tel Aviv Lung Association,
Institutional Review Board
http://www.clinicaltrial.gov – TLA1948
Results
Eighty consecutive eligible patients fulfilled inclusion cri-
teria and were matched to either the training group (40)
or the control group (40). Thirteen patients, 16% (6 in the
rehabilitation group and 7 in the control group) did not
complete the 3 years of follow up (Table 1). All patients
had moderate-severe COPD with moderate peripheralBMC Pulmonary Medicine 2009, 9:26 http://www.biomedcentral.com/1471-2466/9/26
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and respiratory muscle weakness and impaired functional
and maximal exercise capacity. There were no significant
differences in the characteristics of the 80 patients who
initially participated in the PR and control groups (Table
1).
The rate of FEV1 decline was measured after administra-
tion of a 400 ug of salbutamol, a short acting bronchodi-
lator. Figure 1 depicts the changes in FEV1 over time in the
pulmonary rehabilitation and control groups, and dem-
onstrates a significant difference (p < 0.001) between
these two groups. In addition, the decline of FEV1 in the
PR group was significantly lower when comparing each
individual time point (p < 0.05). In the PR group the FEV1
was reduced by 74 ml during the 3 years study, whereas in
the control group it was 149 ml. Table 2 demonstrates an
immediate significant improvement (p < 0.001) in exer-
cise endurance time and work in the PR group, which was
basically maintained during the study duration. In con-
trast, in the control group no significant differences was
observed. BMI improvement in PR treated group was sig-
nificant after more than 1 year, and an opposite change
was observed in the control group.
Discussion
Our study demonstrates that a prolonged rehabilitation
program inhibits the progression of airflow obstruction in
COPD patients. In addition, it increased endurance time
and work, and improved BMI. FEV1 is used in COPD for
disease staging and since it declines progressively, its value
is a predictor of life expectancy. Various exercise tests, dif-
ferent physiological parameters, and BMI are used as sur-
rogates for clinical status assessment. Our study did not
show that PR improved FEV1, which is in accordance to a
previous report, but showed beneficial interference with
its progressive decline.
Previous studies have shown some improvement in FVC
which may have been due to improved respiratory muscle
function and a reduction in small airways disease [3]. The
improvement in FEV1 in those cases was small and not sta-
tistically significant. We noted a significant inhibtion of
the progression of airways obstruction occurring after the
three years of treatment, and thus we speculate that partic-
ipating in the pulmonary rehabilitation program
increased in incremental stages small airways function
and/or recruitment. In addition, the exercise regimen
likely improve secretions evacuation, which can reduce
airways infections/inflammation and decrease COPD
exacerbations. For example, it was recently shown that
moderate to high levels of regular physical activity are
associated with a reduced lung function decline and
COPD risk among smokers [14]. Furthermore, in earlier
reports regular exercise was noted to protect against dis-
eases associated with chronic inflammation [15]. Inflam-
mation is an important element in the pathogenesis of
COPD. The contribution of PR for reduction of FEV1
decline adds an additional beneficial effect of pulmonary
rehabilitation for COPD patients. FEV1decline may serve
as a predictor of risk death from COPD, and therefore PR
should be considered as a disease modifier [16]. The
improvement of endurance time and work noted in the
Table 1: Base line characteristics of the study subjects
Control group Rehabilitation group
Completed Withdrawn All Completed Withdrawn All
N o . 3 374 0 3 464 0
Age 62 ± 5.4 64 ± 2.8 63.2 ± 5 63 ± 5.2 63.2 62.6 ± 6
Male 70% 76% 72% 72% 75% 75%
BMI 24.6 ± 1.8 24.2 ± 1.4 24 ± 1.6 24.2 ± 1.9 23.8 ± 1.6 24.1 ± 1.7
FEV1% 44 ± 8 46 ± 7 44 ± 9 47 ± 5 48 ± 6 47 ± 8
FEV1/FVC 0.56 ± 0.06 0.54 ± 0.04 0.52 ± 0.07 0.56 ± 0.08 0.52 ± 0.03 0.54 ± 0.06
Pack year 24 ± 7 27 ± 4 26 ± 8 27 ± 6 30 ± 4 28 ± 10
BMI-body mass index, FEV1%-percent of predicted of forced expiratory volume in 1 second
Table 2: Effect of pulmonary rehabilitation on cycle exercise performance and BMI
Control group Rehabilitation group
Before After 1-year After 3-years Before After 1-year After 3 years P-value
Max. sustained cycle work, W 32 ± 11 30 ± 8 28 ± 8 30 ± 9 76 ± 22 78 ± 24 < 0.01
Max. sustained cycle time, Min. 5.8 ± 0.9 5.6 ± 1.1 5.8 ± 1.1 6 ± 1.1 12.6 ± 4.4 11.8 ± 4 < 0.01
BMI 24.6 ± 1.8 24.4 ± 2.2 21.6 ± 2.4* 24.2 ± 1.9 25.4 ± 2 25.1 ± 2.2 < 0.05
Max. -maximum, W-watts, min.-minutes, *- only 3 years was significant, BMI-body mass indexBMC Pulmonary Medicine 2009, 9:26 http://www.biomedcentral.com/1471-2466/9/26
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trial is consistent with previous reports [17]. One possibil-
ity no significant differences were noted regarding exacer-
bation-related hospitalizations in these two groups, may
relate to the higher accessibility to medical care in the
patients enrolled in our study, relative to the regular
COPD patient. A randomized study would be preferable,
in
Match study the control subjects who are 'matched' with
the treated subjects on background covariates that the
investigator believes need to be controlled [11]. Finally,
since this study included patients with severe disease, the
duration of three years to complete the study may have
contributed to the relatively high number of dropouts
(including death), for which we could not identify a spe-
cific reason.
Conclusion
Three years of pulmonary rehabilitation has an important
beneficial impact on the rate of FEV1 decline, in addition
to previously reported advantages of this treatment
modality, for COPD patients.
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